about
Bipolar disorder and mechanisms of action of mood stabilizersDecreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjectsFuture Directions for Pharmacotherapies for Treatment-resistant Bipolar DisorderThe Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?Bipolar disorder: candidate drug targets.Relationship between depression and borderline personality disorder.Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents.Endophenotypes in bipolar disorder.Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trialThe prominent role of stimulus processing: cholinergic function and dysfunction in cognition.Depression and antidepressants: molecular and cellular aspects.Psychiatry-epitomes of progress: cholinergic hypersensitivity in patients with affective disorders.Is cholinergic sensitivity a genetic marker for the affective disorders?Effects of lithium treatment in vitro and in vivo on acetylcholine metabolism in rat brain.A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania.Acetylcholine content in rat brain is elevated by status epilepticus induced by lithium and pilocarpine.Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients.
P2860
Q22252332-03177C9D-9809-421F-8FDA-43323FFA5CBAQ24654110-F59B1204-53F1-42B3-AD78-5C7BD410E0B6Q26782989-B6BEC3A0-BD7D-49D4-B526-DA56DB939963Q28082434-21378FFA-3DA9-4576-A803-212A0C21CBE7Q28751133-096F9B17-D304-4DAE-A38F-11BBDF07E1F3Q31533726-02B2E81B-12B1-4A01-9B7B-ABCDAEDC8591Q34622385-50E789D1-F19C-4D55-BEBF-621FE89D9BE0Q34626051-E23857C3-299D-489B-A7A2-F4441E9F1769Q34766451-943D7078-39E2-498E-9AEB-01F088887AF1Q35054681-85637FFC-7555-48CC-A237-D344C600E666Q35648180-B8050623-7D95-4899-8645-D7BD216B90E9Q35689769-13A43EDF-577C-4B83-A8FE-6931D17F6CA0Q37517285-4B884639-A341-4ED8-9B20-C1FEFDC5DA0FQ39346171-D3EEED86-5FC3-4F19-84D0-08ECEAD5606CQ40511237-60E3E65A-9B60-4DCE-B32F-106D9E45725AQ41743154-7CC537B9-0943-4D2B-B7B7-0B58F7B80A51Q42164465-FC951D6C-B85C-4B10-8AE7-88FA2877463FQ42218984-766BA92C-CE3E-4111-B8EF-E0F33288508CQ51814037-6ABA1989-379C-4D5E-A3D9-8B90D2A1BE4D
P2860
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年学术文章
@wuu
1978年学术文章
@zh-cn
1978年学术文章
@zh-hans
1978年学术文章
@zh-my
1978年学术文章
@zh-sg
1978年學術文章
@yue
1978年學術文章
@zh
1978年學術文章
@zh-hant
name
Physostigmine in mania.
@en
type
label
Physostigmine in mania.
@en
prefLabel
Physostigmine in mania.
@en
P2093
P1433
P1476
Physostigmine in mania.
@en
P2093
Defraites E
Hollister LE
P304
P356
10.1001/ARCHPSYC.1978.01770250121012
P407
P577
1978-01-01T00:00:00Z